Business
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting preclinical data from SG293, its CD19-directed in vivo CAR T product candidate, has been accepted for oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting taking place May 11-15, 2026 in Boston, MA. Oral Presentation: Title:Potent, safe, and cell-
About this update from Sana Biotechnology, Inc.
[{"type":"image","alt":"Sana Biotechnology, Inc","displaySize":"","headline":null,"caption":"Sana Biotechnology, Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":85,"url":"https://media.zenfs.com/en/globenewswire.com/c8ec5ce7c1d4da77d92cdc607ff85c4e"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1FAbLyhhxj0MOkOtuA91gA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExOQ--/https://media.zenfs.com/en/globenewswire.com/c8ec5ce7c1d4da77d92cdc607ff85c4e","width":300,"height":85}},"lazy":false},{"type":"text","content":"SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting preclinical data from SG293, its CD19-directed in vivo CAR T product candidate, has been accepted for oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting taking place May 11-15, 2026 in Boston, MA.","length":460,"tagName":"p"},{"type":"text","content":"Oral Presentation:","length":18,"tagName":"p"},{"type":"table","headerItems":[],"items":[{"val":[{"style":"max-width:20%;width:20%;min-width:20%;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Title:","length":6,"tagName":"p","attribs":{}}]},{"style":"max-width:80%;width:80%;min-width:80%;text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Potent, safe, and cell-specific in vivo generation of CAR-T cells in NHPs with SG293","length":84,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Summary:","length":8,"tagName":"p","attribs":{}}]},{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"SG293 represents a differentiated approach for enabling potent and precise in vivo CAR T therapy for both oncology and autoimmune indications, potentially avoiding key off-target concerns.","length":193,"tagName":"p","attribs":{}}]}]},{"val":[{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Session:","length":8,"tagName":"p","attribs":{}}]},{"style":"text-align:left;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Adva...